Moderna, Inc. (MRNA)
138.82
-6.31
(-4.35%)
USD |
NASDAQ |
Aug 24, 16:00
139.00
+0.18
(+0.13%)
After-Hours: 20:00
Moderna Gross Profit Margin (Quarterly) : -7.59% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -7.59% |
| March 31, 2026 | -160.7% |
| December 31, 2025 | 23.45% |
| September 30, 2025 | 74.51% |
| June 30, 2025 | -23.94% |
| March 31, 2025 | -19.44% |
| December 31, 2024 | 17.29% |
| September 30, 2024 | 69.60% |
| June 30, 2024 | 35.27% |
| March 31, 2024 | 20.96% |
| December 31, 2023 | 59.65% |
| September 30, 2023 | -35.99% |
| June 30, 2023 | -138.7% |
| March 31, 2023 | 53.48% |
| December 31, 2022 | 60.23% |
| September 30, 2022 | 63.40% |
| June 30, 2022 | 69.12% |
| March 31, 2022 | 81.89% |
| Date | Value |
|---|---|
| December 31, 2021 | 85.58% |
| September 30, 2021 | 84.06% |
| June 30, 2021 | 81.19% |
| March 31, 2021 | 89.26% |
| December 31, 2020 | 97.26% |
| September 30, 2020 | 94.62% |
| June 30, 2020 | 88.55% |
| March 31, 2020 | 11.21% |
| December 31, 2019 | 36.40% |
| September 30, 2019 | 57.17% |
| June 30, 2019 | 42.67% |
| March 31, 2019 | 54.35% |
| December 31, 2018 | 79.25% |
| September 30, 2018 | 84.48% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 93.56% |
| September 30, 2017 | 87.92% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| BioNTech SE | -169.3% |
| Kailera Therapeutics, Inc. | -- |
| Sarepta Therapeutics, Inc. | 60.18% |
| Replimune Group, Inc. | -- |
| Intellia Therapeutics, Inc. | 72.58% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -37.92% |
| Return on Assets | -26.73% |
| Return on Invested Capital | -33.58% |
| Profit Margin (Quarterly) | -539.3% |
| Operating Margin (Quarterly) | -562.1% |
| Return on Net Operating Assets | -86.34% |